89 related articles for article (PubMed ID: 19666212)
1. A potential role for crystallization inhibitors in treatment of Alzheimer's disease.
Grases F; Costa-Bauzà A; Prieto RM
Med Hypotheses; 2010 Jan; 74(1):118-9. PubMed ID: 19666212
[TBL] [Abstract][Full Text] [Related]
2. Role of melatonin in Alzheimer-like neurodegeneration.
Wang JZ; Wang ZF
Acta Pharmacol Sin; 2006 Jan; 27(1):41-9. PubMed ID: 16364209
[TBL] [Abstract][Full Text] [Related]
3. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties.
Fernández-Bachiller MI; Pérez C; Campillo NE; Páez JA; González-Muñoz GC; Usán P; García-Palomero E; López MG; Villarroya M; García AG; Martínez A; Rodríguez-Franco MI
ChemMedChem; 2009 May; 4(5):828-41. PubMed ID: 19308922
[TBL] [Abstract][Full Text] [Related]
4. The neuroprotective role of melatonin against amyloid beta peptide injected mice.
Masilamoni JG; Jesudason EP; Dhandayuthapani S; Ashok BS; Vignesh S; Jebaraj WC; Paul SF; Jayakumar R
Free Radic Res; 2008 Jul; 42(7):661-73. PubMed ID: 18654881
[TBL] [Abstract][Full Text] [Related]
5. The human pineal gland and melatonin in aging and Alzheimer's disease.
Wu YH; Swaab DF
J Pineal Res; 2005 Apr; 38(3):145-52. PubMed ID: 15725334
[TBL] [Abstract][Full Text] [Related]
6. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease.
Brunner P; Sözer-Topcular N; Jockers R; Ravid R; Angeloni D; Fraschini F; Eckert A; Müller-Spahn F; Savaskan E
Eur J Histochem; 2006; 50(4):311-6. PubMed ID: 17213040
[TBL] [Abstract][Full Text] [Related]
7. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells.
Feng Z; Zhang JT
J Pineal Res; 2004 Nov; 37(4):257-66. PubMed ID: 15485552
[TBL] [Abstract][Full Text] [Related]
8. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography.
Mahlberg R; Walther S; Kalus P; Bohner G; Haedel S; Reischies FM; Kühl KP; Hellweg R; Kunz D
Neurobiol Aging; 2008 Feb; 29(2):203-9. PubMed ID: 17097768
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of melatonin in experimental models of Alzheimer disease.
Cheng Y; Feng Z; Zhang QZ; Zhang JT
Acta Pharmacol Sin; 2006 Feb; 27(2):129-39. PubMed ID: 16412260
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
11. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease.
Feng Z; Qin C; Chang Y; Zhang JT
Free Radic Biol Med; 2006 Jan; 40(1):101-9. PubMed ID: 16337883
[TBL] [Abstract][Full Text] [Related]
12. Melatonin: new places in therapy.
Maharaj DS; Glass BD; Daya S
Biosci Rep; 2007 Dec; 27(6):299-320. PubMed ID: 17828452
[TBL] [Abstract][Full Text] [Related]
13. Melatonin oxidative stress and neurodegenerative diseases.
Srinivasan V
Indian J Exp Biol; 2002 Jun; 40(6):668-79. PubMed ID: 12587715
[TBL] [Abstract][Full Text] [Related]
14. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism.
Gunasingh MJ; Philip JE; Ashok BS; Kirubagaran R; Jebaraj WC; Davis GD; Vignesh S; Dhandayuthapani S; Jayakumar R
Life Sci; 2008 Jul; 83(3-4):96-102. PubMed ID: 18590917
[TBL] [Abstract][Full Text] [Related]
15. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease.
Feng Z; Chang Y; Cheng Y; Zhang BL; Qu ZW; Qin C; Zhang JT
J Pineal Res; 2004 Sep; 37(2):129-36. PubMed ID: 15298672
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of oxidant mechanisms in Alzheimer's disease.
Moreira PI; Smith MA; Zhu X; Santos MS; Oliveira CR; Perry G
Expert Rev Neurother; 2004 Nov; 4(6):995-1004. PubMed ID: 15853526
[TBL] [Abstract][Full Text] [Related]
17. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.
Lahiri DK; Chen DM; Lahiri P; Bondy S; Greig NH
Ann N Y Acad Sci; 2005 Nov; 1056():430-49. PubMed ID: 16387707
[TBL] [Abstract][Full Text] [Related]
18. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Olcese JM; Cao C; Mori T; Mamcarz MB; Maxwell A; Runfeldt MJ; Wang L; Zhang C; Lin X; Zhang G; Arendash GW
J Pineal Res; 2009 Aug; 47(1):82-96. PubMed ID: 19538338
[TBL] [Abstract][Full Text] [Related]
19. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models.
Joo Y; Kim HS; Woo RS; Park CH; Shin KY; Lee JP; Chang KA; Kim S; Suh YH
Mol Pharmacol; 2006 Jan; 69(1):76-84. PubMed ID: 16223958
[TBL] [Abstract][Full Text] [Related]
20. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.
Pappolla MA; Chyan YJ; Poeggeler B; Frangione B; Wilson G; Ghiso J; Reiter RJ
J Neural Transm (Vienna); 2000; 107(2):203-31. PubMed ID: 10847561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
